(0.13%) 5 138.25 points
(0.09%) 38 475 points
(0.21%) 17 883 points
(-0.23%) $83.66
(1.82%) $1.958
(0.08%) $2 349.00
(0.44%) $27.66
(1.58%) $936.65
(-0.15%) $0.933
(-0.26%) $11.00
(-0.26%) $0.798
(1.19%) $92.97
Live Chart Being Loaded With Signals
Bukwang Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. It manufactures oral solid dosage forms, injections, oral solutions, external-use solutions, and ointments...
Stats | |
---|---|
本日の出来高 | 97 884.00 |
平均出来高 | 689 294 |
時価総額 | 408.25B |
EPS | KRW0 ( 2024-04-22 ) |
次の収益日 | ( KRW0 ) 2024-05-13 |
Last Dividend | KRW0 ( N/A ) |
Next Dividend | KRW0 ( N/A ) |
P/E | 0 |
ATR14 | KRW7.24 (0.12%) |
ボリューム 相関
Bukwang Pharmaceutical 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Bukwang Pharmaceutical 相関 - 通貨/商品
Bukwang Pharmaceutical 財務諸表
Annual | 2023 |
収益: | KRW125.93B |
総利益: | KRW50.05B (39.74 %) |
EPS: | KRW-457.67 |
FY | 2023 |
収益: | KRW125.93B |
総利益: | KRW50.05B (39.74 %) |
EPS: | KRW-457.67 |
FY | 2022 |
収益: | KRW190.91B |
総利益: | KRW79.43B (41.61 %) |
EPS: | KRW-62.07 |
FY | 2021 |
収益: | KRW182.49B |
総利益: | KRW75.76B (41.51 %) |
EPS: | KRW-8.74 |
Financial Reports:
No articles found.
Bukwang Pharmaceutical
Bukwang Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. It manufactures oral solid dosage forms, injections, oral solutions, external-use solutions, and ointments. The company offers products in various therapeutic areas, including liver disease treatments, such as Levovir and Legalon; diabetic complication products comprising Dexid and Thioctacid; CNS disorder drugs consisting of Lonasen, Ixel, and Orfil; and respiratory disease treatments, which comprise Azeptin and Asima. It also provides OTC products; toothpastes, and hair and skin care goods; and nutritional supplements. In addition, the company offers products for antihistamines, hepatitis and gastrointestinal, sedative and antidote, anti-cancer, thyroid and osteoporosis, diabetes, obstetrics, urinogenital, cardiovascular, dermatology, obesity, pain relief, and muscle relaxant. Further, it provides products for bruises, skin and mucous membrane, rhinitis, cold symptoms, cough, phlegm and asthma, rheumatoid arthritis, osteoarthritis, pain caused by cold and fever, dysmenorrhea, NSAIDs, inflammation, joint inflammation, tinea pedis, infected wounds, dermatitis, antivirals-herpes, eczema, diarrhea, dyspepsia, sense of distension, anti-histamine, anti-ulcer, constipation, anemia, pregnant multivitamins, candidiasis, athlete's foot, onychomycosis, stomatitis, pimple, acne, physical fatigue, neuralgia, myalgia, and arthralgia. Additionally, the company offers medicines for period of lactation, rickets, night blindness, varicose vein, and sputum; and quasi drugs and medical devices, as well as health functional food. It also develops anti-diabetes compound with Melior Pharmaceuticals; and anti-cancer drugs with LSK BioPartners, as well as cell therapies using adult stem cells, as well as holds a license for a novel candidate to treat movement disorder in Parkinson's disease patients. The company was founded in 1960 and is based in Seoul, South Korea.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。